

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. TSRI 609.1		SERIAL NO. 09/581,044	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Lee, et al.			
				FILING DATE 06/08/2000		GROUP 1653	
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	1	5,157,041	10/20/1992	Handa, et al.			
	2	5,354,866	10/11/1994	Kempf, et al.			
	3	5,502,060	3/26/1996	Thompson, et al.			
	4	5,541,321	7/30/1996	Baker, et al.			
	5	5,567,823	10/22/1996	Tien, et al.			
	6	5,733,906	3/31/1998	Jungheim, et al.			

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	7	WO 93/23361	11/25/1993				
	8	EP 0 751 145 A2	1/2/1997				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

JSL	9	✓	Huff, "HIV Protease: A Novel Chemotherapeutic Target for AIDS", <u>J. Med. Chem.</u> 34: 2305-2314 (1991)
	10		<del>Dreyer, et al., "A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically", <u>Biochemistry</u> 32: 937-947 (1993)</del>
JSL	11	✓	Otto, et al., "In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 Symmetrical inhibitors of HIV type 1 protease", <u>Proc. Natl. Acad. Sci. USA</u> 90: 7543-7547 (1993)
JSL	12	✓	Wlodawer, et al., "Structure-Based Inhibitors of HIV-1 Protease", <u>Annu. Rev. Biochem.</u> 62: 543-585 (1993)
JSL	13	✓	Condra, et al., "In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors", <u>Nature</u> 374: 569-571 (1995)
JSL	14	✓	Wlodawer, et al., "Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus", <u>Nature Struct. Biol.</u> 2: 480-488 (1995)
JSL	15	✓	Erickson, "The not-so-great escape", <u>Nature Struct. Biol.</u> 2: 523-529 (1995)
JSL	16	✓	Slee, et al., "Selectivity in the Inhibition of HIV and FIV Protease: Inhibitory and Mechanistic Studies of Pyrrolidine-Containing $\alpha$ -Keto Amide and Hydroxyethylamine Core Structures", <u>J. Am. Chem. Soc.</u> 117: 11867-11878 (1995)
JSL	17	✓	Budt, et al., "HIV Protease Inhibitor HOE/BAY 793, Structure-Activity Relationships in a Series of C <sub>2</sub> -Symmetric Diols", <u>Bioorg. Med. Chem.</u> 3: 559-571 (1995)
JSL	18	✓	Gulnik, et al., "Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutants Selected under Drug Pressure", <u>Biochemistry</u> 34: 9282-9287 (1995)
JSL	19	✓	Erickson, et al., "Structural Mechanisms of HIV Drug Resistance", <u>Annu. Rev. Pharmacol. Toxicol.</u> 36: 545-571 (1996)
EXAMINER			DATE CONSIDERED
Jeffrey E. Russell			October 11, 2001

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. TSRI 609.1		SERIAL NO. 09/581,044	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Lee, et al.			
		FILING DATE 6/ 8/ 2000		GROUP 1653	

PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

RECEIVED  
FEB 02 2001  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

JAR	20	✓	De Lucca, et al., "Cyclic HIV Protease Inhibitors capable of displacing the active site structural water molecule" <u>Drug Discovery Today 2: 6-18 (1997)</u>
JAR	21	✓	Wilson, et al., "Escape Mutants of HIV-1 Proteinase: Enzymic Efficiency and Susceptibility to Inhibition", <u>Biochim. Biophys. Acta 1339: 113-115 (1997)</u>
JAR	22	✓	Vacca, et al., "Clinically Effective HIV-1 Protease Inhibitors", <u>Drug Discovery Today 2: 261-272 (1997)</u>
JAR	23	✓	Wong, et al., "Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia", <u>Science 278: 1291-1295 (1997)</u>
JAR	24	✓	Finzi, et al., "Identification of a Reservoir of HIV-1 in Patients on Highly Active Antiretroviral Therapy", <u>Science 278: 1295-1300 (1997)</u>
JAR	25	✓	Lee, et al., "Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV <i>in vitro</i> and <i>ex vivo</i> ", <u>Proc. Natl. Acad. Sci. USA 95: 939-944 (1998)</u>

EXAMINER Jeffrey E. Russel	DATE CONSIDERED October 11, 2001
-------------------------------	-------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.